Prof. Dr. Gerold Schuler

Medizinische Fakultät Lehrstuhl für Haut- und Geschlechtskrankheiten

FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt M, Eigentler T, Berking C, Schadendorf D, et al. Conference contribution Can checkpoint inhibitor therapy improve response to chemotherapy? (2018) Kirchberger MC, Schilling B, Haferkamp S, Boßerhoff AK, Schuler G, Heinzerling L Journal article The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma (2018) Simon B, Wiesinger M, Maerz J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, et al. Journal article The simultaneous siRNA-mediated downregulation of PD-1 and CTLA-4 to improve CAR-T cell immunotherapy of melanoma (2018) Simon B, Harrer D, Schuler-Thurner B, Dörrie J, Schaft N, Schuler G, Uslu U Conference contribution Understanding microRNA-mediated immunogenicity of dendritic cells using an integrative approach (2018) Lai X, Dreyer F, Jaitly T, Cantone M, Gerer KF, Schuler G, Dörrie J, et al. Conference contribution Managing toxicities of immunotherapies - a side effect register for rare and severe side effects of checkpoint Inhibitor therapy (2018) Heinzerling L, Schuler G Conference contribution Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome (2018) Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L Journal article Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, et al. Journal article Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients (2018) Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L Journal article Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports (2018) Schliep S, Agaimy A, Kiesewetter F, Schuler G, Heinzerling L, Cavallaro AJ Journal article